Therefore, specific inhibitors targeting upstream regulators or downstream effectors of the PI3K-AKT signaling pathway, such as human epidermal growth factor receptor 2 (HER2) or mammalian target of rapamycin (mTOR), were developed as novel strategies to increase the chemotherapeutic sensitivity of cancer cells [26, 29]. Here, ERBB2 is linked to cancer.